Articles tagged with Small Cell Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Breakthrough research recommends that more than one N1 node be removed and evaluated during surgery for non-small cell lung cancer (NSCLC). The study found that many cancers were identified in N1 nodes adjacent to the bronchi, highlighting the need for expanded lymph node evaluation.
Researchers identify a molecular target that enhances treatment for EGFR-mutant lung cancers prevalent in Asia. Disrupting this protective system can shrink tumors in laboratory models.
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
ICIs combined with chemotherapy shows promise for treating EGFR-TKI-resistant NSCLC, improving PFS and OS. Acceptable safety profile for ICIs-chemotherapy regimen, suggesting potential as therapeutic option.
A population-based cohort study found that individuals following high-glycemic index diets had a 13% higher chance of developing lung cancer compared to those on low-GI diets. In contrast, those consuming high-glycemic load diets experienced a 28% lower risk of lung cancer.
Cancer researchers at Cold Spring Harbor Laboratory have identified key proteins that determine the behavior of two hard-to-treat carcinomas, pancreatic cancer and tuft cell lung cancer. These findings could lead to new therapies targeting specific vulnerabilities in these cancers.
Dr. Lovly brings nearly two decades of experience in clinical care, research and academic leadership to her new role, shaping the modern landscape of lung cancer care. Her expertise in precision medicine will be instrumental in accelerating progress for patients with lung cancer across the country.
The American Society for Radiation Oncology (ASTRO) has announced three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer Therapy Challenge. The selected projects aim to improve therapies and outcomes for patients with limited-stage SCLC through immunotherapy and radiation techniques.
A new study may transform the diagnosis of Britain's number one cancer, lung cancer. Researchers are investigating whether low-dose CT scans can detect lung cancers earlier than current chest X-rays. The study aims to identify which patients would benefit from these more accurate scans.
The phase 3 FLAURA2 study shows that adding platinum-pemetrexed to osimertinib improves overall survival in patients with newly diagnosed EGFR-mutated advanced NSCLC. Median overall survival was 47.5 months, compared to 37.6 months with osimertinib alone.
Researchers are collecting toenail clippings from Canadians to estimate a person's lung-cancer risk based on long-term radon exposure. The study aims to provide critical data for early screening and diagnosis of lung cancer.
A new grading system for invasive squamous cell carcinoma of the lung has been proposed based on tumor budding, with tumors classified as low-grade (0-9 buds/0.785 mm²) or high-grade (≥10 buds/0.785 mm²). The system was validated in a test set and demonstrated improved prognostic accuracy and guide treatment decisions.
A patient-reported outcomes analysis suggests that twice-daily radiation is associated with better quality of life and longer survival compared to once-daily radiation in patients with limited-stage small cell lung cancer. The study found less clinically meaningful decline in quality of life among those receiving twice-daily radiation.
Researchers identify basal stem-like cells as the origin of small cell lung cancer, providing a major shift in understanding this deadly disease. The study's findings allow for exploration of strategies to prevent the disease before it evades the immune system and spreads.
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
Researchers discover lung cancer cells in the brain form synapses with neurons, promoting tumor growth. This finding highlights the importance of neural signaling in cancer growth and suggests novel therapies to interrupt this signaling.
Research presents IFITM3 as critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. Enhanced MHC-I expression improves antigen presentation and boosts CD8⁺ T cell infiltration.
Researchers found that a faster rate of binding does not always translate to greater potency, as the study's lead author David Heppner explained. The team proposed a two-step design process balancing inactivation efficiency rates with target selectivity and other parameters to identify promising compounds.
A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...
A five-year analysis of the CheckMate-816 clinical trial shows that immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival. Patients who achieved complete remission had a 95% five-year survival rate.
The study evaluated the mutation profiles of lung squamous cell carcinoma (LSCC) detected by next-generation sequencing to assess relationships with clinicopathological parameters. Detection of mutations revealed associations between certain genes, such as PIK3CA and NF1, with specific histopathological features.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
A single-arm trial evaluated the safety and efficacy of first-line camrelizumab, apatinib, and chemotherapy in untreated extensive-stage small-cell lung cancer patients. The treatment demonstrated an ORR of 88.9% and median PFS and OS of 7.3 and 17.3 months, respectively.
The European Lung Cancer Congress 2025 will take place in Paris from March 26-29, featuring renowned experts discussing the latest research on lung cancer prevention, diagnosis, and treatment. The congress will also include award lectures and live streaming of the event.
Researchers found that aggressive lung cancer cells can generate their own electrical activity, building an independent network within the tumour. This property is distinct from most other cancer types and may drive the tumour's ability to grow and spread.
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
Researchers analyzed tumor samples from 64 SCLC patients, identifying promising results for biomarkers DLL3 and TTF-1. These biomarkers showed potential as targets for therapies like Tarlatamab and improved survival rates in patients with TTF-1-positive tumors.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
A new subtype of small cell lung cancer has been identified that primarily affects younger people who have never smoked. The disease has distinct clinical and pathological features, and a unique molecular mechanism involving chromothripsis-mediated DNA damage.
A new study found that Hispanic non-small cell lung cancer patients in South Florida tend to be diagnosed at earlier stages than White patients, with a lower likelihood of advanced-stage diagnoses. This disparity disappears when examining ethnic subpopulations within the Hispanic population.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
The study identified RNF144B as a tumour suppressor that prevents genomic instability, but low expression leads to poor prognosis and treatment resistance in lung adenocarcinoma. The research suggests that even non-mutated genes like RNF144B can have a significant impact on cancer development.
Researchers at Osaka University have developed molecules that can correct improper splicing of a vital tumor suppressor gene in neuroendocrine cancers. The study demonstrates that these splice-switching oligonucleotides can significantly reduce viable cancer cells and tumor size in mice, suggesting a novel therapeutic approach for intr...
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers at Weill Cornell Medicine have developed a mouse model that illuminates the process of histological transformation, where adenocarcinoma transforms into aggressive small cell lung cancer. The study suggests targeting Myc proteins as potential therapeutic approaches for this deadly type of cancer.
Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.
Small cell lung cancers metastasize to the brain by convincing astrocytes they are baby neurons in need of protection. Blocking this signal may slow or stop brain metastasis growth, according to a Stanford Medicine study.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
Tedopi, a T-cell epitope-based cancer vaccine, has demonstrated improved overall survival and a better safety profile compared to chemotherapy in HLA-A2 positive patients with advanced or metastatic NSCLC who have progressed after immune checkpoint inhibitors. The Phase 3 trial showed a significant reduction in the risk of death by 41%.
Researchers at MedUni Vienna's Department of Thoracic Surgery have made key findings in small-cell lung cancer, including the identification of tumor subgroups associated with varying clinical behaviors. They also propose promising therapeutic strategies for patients with characteristic molecular profiles.
A phase II trial showed that patients with extensive stage SCLC expressing the Schlafen-11 gene had significantly longer progression-free survival when treated with atezolizumab and talazoparib. The study demonstrates improved outcomes for patients with SLFN11-positive SCLC, paving the way for personalized therapy approaches.
A new molecular imaging radiotracer, <sup> 68 </sup> Ga-PentixaFor, demonstrates high image contrast in various cancers, including hematologic malignancies and small cell lung cancer. This agent targets the C-X-C motif chemokine receptor 4 (CXCR4), which is a predictor of poor prognosis in cancer patients.
A new study reveals that different SCLC subtypes have specific molecular characteristics, leading to varying responses to cancer treatment. The research provides a basis for developing targeted and personalized treatment approaches tailored to each subtype.
Scientists at Northwestern University have identified a new gene that activates an aggressive subtype of small-cell lung cancer with no current effective treatment. Deleting this gene kills cancer cells in deadly subtype.
Researchers discovered that combining a new target with an old chemotherapy drug can reduce resistance and potentially improve treatment outcomes for small cell lung cancer. The study used mouse models to show that inhibiting a protein called SMYD3, along with cyclophosphamide, stopped tumors in their tracks.
The KEYNOTE-604 study shows that pembrolizumab-based combination with etoposide and platinum significantly improves progression-free survival and overall survival in patients with previously untreated ES-SCLC. Long-term follow-up data also reveal durable responses and manageable safety profiles.
Researchers at Cold Spring Harbor Laboratory have discovered a protein interaction that may be an Achilles heel of tuft cell lung cancer. Disrupting this interaction could lead to more targeted therapies for the deadly disease, which originates from cells known as tuft cells.
A meta-analysis published in The Lancet Oncology suggests that targeted radiation therapy, which spares healthy brain tissue, is equitable to whole brain radiation therapy for patients with small cell lung cancer and brain metastases. This approach may improve their care experience with fewer negative cognitive consequences.
Researchers at MedUni Vienna identified five distinct subtypes of small cell lung cancer, each responding differently to therapies. High ASCL1 expression is linked to poor survival, while high POU2F3 expression correlates with better outcomes and sensitivity to standard chemotherapeutics.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
Patients with severe coronary artery calcium have a significantly increased risk of major adverse cardiovascular events during thoracic radiation therapy for non-small cell lung cancer. The study found that patients with severe coronary artery calcium had a 21.4 times increased risk compared to those with no coronary artery calcium.
A prospective study found that MRI outperformed conventional tests and FDG PET/CT for various staging endpoints in SCLC. Whole-body MRI and FDG PET/MRI were more accurate than FDG PET/CT for assessing local invasion extent.
A study analyzed open and closed insurance claims to assess practice behavior changes after durvalumab approval. The results showed a low rate of durvalumab utilization, with higher rates in patients over 65 and treated in the Midwest.